Related Experiment Video
Updated: May 22, 2026
05:39
Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
Molecular target based combinational therapeutic approaches in thyroid cancer
Shilpi Rajoria1, Robert Suriano, Andrea L George
1Department of Microbiology and Immunology, New York Medical College, Valhalla, New York, 10595, USA.
Journal of Translational Medicine
|May 3, 2012
Summary
Estrogen promotes thyroid cancer growth by stimulating angiogenesis via vascular endothelial growth factor (VEGF). Anti-estrogens like fulvestrant and 3,3'-diindolylmethane inhibit this process, offering potential thyroid cancer therapies.
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Background:
- Thyroid cancer growth depends on angiogenesis.
- Estrogen may drive thyroid cancer aggressiveness and incidence in women.
- Estrogen's role in breast cancer angiogenesis suggests a similar role in thyroid cancer.
Purpose of the Study:
- To investigate estrogen's role in thyroid cancer angiogenesis.
- To determine if estrogen induces vascular endothelial growth factor (VEGF) secretion in thyroid cancer cells.
- To evaluate the efficacy of anti-estrogens in inhibiting estrogen-induced angiogenesis in thyroid cancer.
Main Methods:
- Human thyroid cancer cell lines (B-CPAP, CGTH-W-1, ML-1) were treated with estrogen and/or anti-estrogens (fulvestrant, 3,3 -diindolylmethane).
- Conditioned media were applied to human umbilical vein endothelial cells (HUVECs) to assess angiogenesis.
- Vascular endothelial growth factor (VEGF) levels in conditioned media were quantified.
Main Results:
- Estrogen-treated thyroid cancer cells promoted endothelial cell proliferation, migration, and tubulogenesis, indicative of angiogenesis.
- Estrogen-induced VEGF secretion by thyroid cancer cells mediated these angiogenic effects.
- Anti-estrogens significantly inhibited VEGF secretion and subsequent angiogenesis in HUVECs.
Conclusions:
- Estrogen is a key regulator of VEGF secretion in thyroid cells, enhancing thyroid cancer angiogenesis.
- Anti-estrogens demonstrate potential as anti-angiogenic agents for thyroid cancer treatment.
- 3,3 -diindolylmethane shows promise as a natural anti-estrogen for therapeutic regimens.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.